The Rancho Bernardo study also showed an inverse relationship between circulating T levels and plasma VLDL . Most of these studies have also demonstrated an inverse relationship between T levels and both plasma triglycerides 32–34,36 and total cholesterol 32,34. A positive correlation exists between HDL-c and circulating T concentrations, as seen in multiple studies including the San Antonito Heart study , the Tromso study , the Turku Male Aging study , the Rancho Bernardo study , MRFIT and a study from Ghent, Belgium . After adjustment for over 50 variables, those individuals who had received a prescription for T following coronary angiography had a higher incidence of CVD events compared with the group who had not received a T prescription over an average of 27.5 months of follow-up. Importantly, the interpretive value of these randomized controlled trials remains limited, as these studies were not powered to look at CVD events as an outcome. Investigators found no differences in baseline circulating T levels, between the controls and those men who developed incident coronary events, over a decade of follow-up. Subjects enrolled in these studies were followed over a long period of time and then divided into cases or controls, based on development of coronary events. The Rancho Bernardo study followed 1000 men aged 40–79 years over a 12-year period and found no association between plasma T levels and either extant CVD or subsequent cardiovascular morbidity and mortality . Cardiovascular risk increases in men with age in tandem with declining endogenous testosterone (T) production. The meta‐analysis found no significant difference in the occurrence of MACE between the TTh and placebo groups, reinforcing the notion that TTh does not increase overall CV risk. The study specifically examined the incidence of major adverse CV events (MACE) and non‐fatal arrhythmias, including atrial fibrillation (AF). The T‐Trials by Snyder et al.6 assessed TTh's effects on sexual, physical, and cognitive function in older men, monitoring CV events as secondary outcomes (myocardial infarctions, stroke). The study by Basaria et al.10 included doses of T that were higher than the label dose, CV events were not the primary study target and were recorded in a much less than optimal manner. Similar to the previous reports, TRT resulted in a significant increase in hemoglobin levels.36 However, none of the individual prostate-related adverse events significantly differed between groups, including incident prostate cancer, which showed no difference between the TRT group and placebo.34 In 2016, Boyle et al. reported results of a meta-analysis on prostate cancer in TRT trials. The TRT group had a significantly greater incidence of all prostate-related adverse events, with a pooled odds ratio of 1.78 (95% CI, 1.07–2.95). All four studies included in this meta-analysis evaluated the effects of TRT on LVEF as well. The authors also verified that the odds ratio for having hypogonadism was significantly higher in obese men, and there was a statistically significant negative correlation between total T level and BMI.15 Testosterone replacement therapy (TRT) has been shown to decrease fat mass. Whether low T and increased mortality are simply covariates or a causal relationship remains to be proven. Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone. The eligibility criteria for this analysis included all placebo-controlled studies that enrolled men (1) with low or low-normal testosterone levels, and (2) who received any [buy testosterone enanthate](https://truthtube.video/@lindseyljt7939?page=about) formulation for ≥ 3 months. They concluded that TRT for hypogonadism does not appear to increase PSA or the risk of prostate cancer. No significant adverse CV events were noted.28 Further studies are needed to evaluate the clinical effects of TRT in CHF, but [buy testosterone gel online](https://gitea.scivigi.com/adrienemoowatt) appears to be a promising therapeutic option for patients with CHF. No definitive statement can be made regarding the effects of [testosterone for sale](https://git.gasshog.fr/twwnathaniel33) replacement therapy on the levels of either LDL or HDL cholesterol.11 Interpretation of total T concentrations is confounded by variation between individuals, variation in serum SHBG, and variation in androgen sensitivity.6 Furthermore, considerable controversy has arisen regarding the accuracy of currently available commercial [buy testosterone booster](http://55x.top:9300/maloriemoench) assays, especially those showing T levels at the lower end of the "normal" range.4 Free testosterone level may be a more reliable indicator of androgen status, but more studies are needed to confirm this. Low bioavailable testosterone but not total testosterone significantly influenced the all-cause and cardiovascular mortality after the multivariate analysis (Figures 1 and 2), suggesting that this is the more sensitive assay in detecting pathological deficiency and risk compared with other assays. In these models, [buy testosterone gel](https://music.drepic.com/tillylegg26929) appeared to act directly on the vascular smooth muscle, having an antagonistic action on calcium channels similar in effect to that of the anti-anginal drug nifedipine.60In vitro studies of isolated male arteries have demonstrated similar vasodilatory actions. Further work will undoubtedly expand our knowledge regarding the underlying mechanisms and relationships between low testosterone and coronary disease and this will be of great interest. Studies in male animals have shown accelerated atherosclerosis after castration—an effect that is abrogated by androgen replacement therapy.43, 44 One question which remains unanswered is whether low testosterone levels accelerate the development of CAD or whether they are simply a consequence of chronic illness? Some studies measured total [order testosterone online](http://104.254.131.244:3000/launagreenberg) level, [git.esen.gay](https://git.esen.gay/josieashford0) others used free or bioavailable [buy testosterone enanthate online](https://gitea.alexandermohan.com/celinahumes59) or used calculated free-androgen index. English et al.65 demonstrated similar effects, but in the context of chronic testosterone therapy. Rosano et al.39 investigated the acute effects of intravenous [buy testosterone pills](https://89.58.50.249:8443/samuelsani421) therapy in a group of men about to perform exercise, treadmill testing. Similar results were found in larger placebo-controlled randomized controlled trials with improvements in exercise capacity, symptom scores, VO2 max, maximal strength, insulin resistance and a reduction in electrocardiographic Q-T dispersion.74, 75, 76 Although these early studies are positive, more evaluation is needed to elucidate the mechanisms of action of testosterone in heart failure and on the long-term effects of supplementation. In a small randomized placebo controlled clinical trial, Pugh et al.73 demonstrated improvements in exercise capacity and in symptom scores after 12 weeks of [buy testosterone pills](http://114.34.163.174:3333/francescoluna2) therapy in men with heart failure. However, the specific relationship between testosterone and heart failure has not been studied to the same degree as that of [buy testosterone online no prescription](https://channel-u.tv/@sandyckv633584?page=about) and coronary disease. The prevalence of hypogonadism in men with asymptomatic coronary plaque is similar to the prevalence in men with symptomatic CAD and both groups have lower levels of testosterone than men with normal coronary arteries, supporting a causative role more than a symptomatic consequence (Morris PD, 2001. unpublished data).
The Rancho Bernardo study also showed an inverse relationship between circulating T levels and plasma VLDL . Most of these studies have also demonstrated an inverse relationship between T levels and both plasma triglycerides 32–34,36 and total cholesterol 32,34. A positive correlation exists between HDL-c and circulating T concentrations, as seen in multiple studies including the San Antonito Heart study , the Tromso study , the Turku Male Aging study , the Rancho Bernardo study , MRFIT and a study from Ghent, Belgium . After adjustment for over 50 variables, those individuals who had received a prescription for T following coronary angiography had a higher incidence of CVD events compared with the group who had not received a T prescription over an average of 27.5 months of follow-up. Importantly, the interpretive value of these randomized controlled trials remains limited, as these studies were not powered to look at CVD events as an outcome. Investigators found no differences in baseline circulating T levels, between the controls and those men who developed incident coronary events, over a decade of follow-up. Subjects enrolled in these studies were followed over a long period of time and then divided into cases or controls, based on development of coronary events. The Rancho Bernardo study followed 1000 men aged 40–79 years over a 12-year period and found no association between plasma T levels and either extant CVD or subsequent cardiovascular morbidity and mortality . Cardiovascular risk increases in men with age in tandem with declining endogenous testosterone (T) production. The meta‐analysis found no significant difference in the occurrence of MACE between the TTh and placebo groups, reinforcing the notion that TTh does not increase overall CV risk. The study specifically examined the incidence of major adverse CV events (MACE) and non‐fatal arrhythmias, including atrial fibrillation (AF). The T‐Trials by Snyder et al.6 assessed TTh's effects on sexual, physical, and cognitive function in older men, monitoring CV events as secondary outcomes (myocardial infarctions, stroke). The study by Basaria et al.10 included doses of T that were higher than the label dose, CV events were not the primary study target and were recorded in a much less than optimal manner. Similar to the previous reports, TRT resulted in a significant increase in hemoglobin levels.36 However, none of the individual prostate-related adverse events significantly differed between groups, including incident prostate cancer, which showed no difference between the TRT group and placebo.34 In 2016, Boyle et al. reported results of a meta-analysis on prostate cancer in TRT trials. The TRT group had a significantly greater incidence of all prostate-related adverse events, with a pooled odds ratio of 1.78 (95% CI, 1.07–2.95). All four studies included in this meta-analysis evaluated the effects of TRT on LVEF as well. The authors also verified that the odds ratio for having hypogonadism was significantly higher in obese men, and there was a statistically significant negative correlation between total T level and BMI.15 Testosterone replacement therapy (TRT) has been shown to decrease fat mass. Whether low T and increased mortality are simply covariates or a causal relationship remains to be proven. Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone. The eligibility criteria for this analysis included all placebo-controlled studies that enrolled men (1) with low or low-normal testosterone levels, and (2) who received any [buy testosterone enanthate](https://truthtube.video/@lindseyljt7939?page=about) formulation for ≥ 3 months. They concluded that TRT for hypogonadism does not appear to increase PSA or the risk of prostate cancer. No significant adverse CV events were noted.28 Further studies are needed to evaluate the clinical effects of TRT in CHF, but [buy testosterone gel online](https://gitea.scivigi.com/adrienemoowatt) appears to be a promising therapeutic option for patients with CHF. No definitive statement can be made regarding the effects of [testosterone for sale](https://git.gasshog.fr/twwnathaniel33) replacement therapy on the levels of either LDL or HDL cholesterol.11 Interpretation of total T concentrations is confounded by variation between individuals, variation in serum SHBG, and variation in androgen sensitivity.6 Furthermore, considerable controversy has arisen regarding the accuracy of currently available commercial [buy testosterone booster](http://55x.top:9300/maloriemoench) assays, especially those showing T levels at the lower end of the "normal" range.4 Free testosterone level may be a more reliable indicator of androgen status, but more studies are needed to confirm this. Low bioavailable testosterone but not total testosterone significantly influenced the all-cause and cardiovascular mortality after the multivariate analysis (Figures 1 and 2), suggesting that this is the more sensitive assay in detecting pathological deficiency and risk compared with other assays. In these models, [buy testosterone gel](https://music.drepic.com/tillylegg26929) appeared to act directly on the vascular smooth muscle, having an antagonistic action on calcium channels similar in effect to that of the anti-anginal drug nifedipine.60In vitro studies of isolated male arteries have demonstrated similar vasodilatory actions. Further work will undoubtedly expand our knowledge regarding the underlying mechanisms and relationships between low testosterone and coronary disease and this will be of great interest. Studies in male animals have shown accelerated atherosclerosis after castration—an effect that is abrogated by androgen replacement therapy.43, 44 One question which remains unanswered is whether low testosterone levels accelerate the development of CAD or whether they are simply a consequence of chronic illness? Some studies measured total [order testosterone online](http://104.254.131.244:3000/launagreenberg) level, [git.esen.gay](https://git.esen.gay/josieashford0) others used free or bioavailable [buy testosterone enanthate online](https://gitea.alexandermohan.com/celinahumes59) or used calculated free-androgen index. English et al.65 demonstrated similar effects, but in the context of chronic testosterone therapy. Rosano et al.39 investigated the acute effects of intravenous [buy testosterone pills](https://89.58.50.249:8443/samuelsani421) therapy in a group of men about to perform exercise, treadmill testing. Similar results were found in larger placebo-controlled randomized controlled trials with improvements in exercise capacity, symptom scores, VO2 max, maximal strength, insulin resistance and a reduction in electrocardiographic Q-T dispersion.74, 75, 76 Although these early studies are positive, more evaluation is needed to elucidate the mechanisms of action of testosterone in heart failure and on the long-term effects of supplementation. In a small randomized placebo controlled clinical trial, Pugh et al.73 demonstrated improvements in exercise capacity and in symptom scores after 12 weeks of [buy testosterone pills](http://114.34.163.174:3333/francescoluna2) therapy in men with heart failure. However, the specific relationship between testosterone and heart failure has not been studied to the same degree as that of [buy testosterone online no prescription](https://channel-u.tv/@sandyckv633584?page=about) and coronary disease. The prevalence of hypogonadism in men with asymptomatic coronary plaque is similar to the prevalence in men with symptomatic CAD and both groups have lower levels of testosterone than men with normal coronary arteries, supporting a causative role more than a symptomatic consequence (Morris PD, 2001. unpublished data).